Prev Chronic Dis. 2019 May 02;16:E54. doi: 10.5888/pcd16.180336.
Developing a Web-Based Cost Assessment Tool for Colorectal Cancer Screening Programs.
Preventing chronic disease
Sonja Hoover, Sujha Subramanian, Florence Tangka
Affiliations
Affiliations
- RTI International, Waltham, Massachusetts.
- 307 Waverley Oaks Rd, Suite 101, Waltham, MA 02452. E-mail: [email protected].
- Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia.
PMID: 31050637
PMCID: PMC6513486 DOI: 10.5888/pcd16.180336
Abstract
INTRODUCTION: We developed a web-based cost assessment tool (CAT) to collect cost data as an improvement from a desktop instrument to perform economic evaluations of the Centers for Disease Control and Prevention's (CDC's) Colorectal Cancer Control Program (CRCCP) grantees. We describe the development of the web-based CAT, evaluate the quality of the data obtained, and discuss lessons learned.
METHODS: We developed and refined a web-based CAT to collect 5 years (2009-2014) of cost data from 29 CRCCP grantees. We analyzed funding distribution; costs by budget categories; distribution of costs related to screening promotion, screening provision, and overarching activities; and reporting of screenings for grantees that received funding from non-CDC sources compared with those grantees that did not.
RESULTS: CDC provided 85.6% of the resources for the CRCCP, with smaller amounts from in-kind contributions (7.8%), and funding from other sources (6.6%) (eg, state funding). Grantees allocated, on average, 95% of their expenditures to specific program activities and 5% to other activities. Some non-CDC funds were used to provide screening tests to additional people, and these additional screens were captured in the CAT.
CONCLUSION: A web-based tool can be successfully used to collect cost data on expenditures associated with CRCCP activities. Areas for future refinement include how to collect and allocate dollars from other sources in addition to CDC dollars.
References
- Cancer Epidemiol. 2016 Dec;45 Suppl 1:S37-S42 - PubMed
- Cancer Epidemiol. 2016 Dec;45 Suppl 1:S30-S36 - PubMed
- Cancer Epidemiol. 2016 Dec;45 Suppl 1:S4-S12 - PubMed
- Cancer. 2013 Aug 1;119 Suppl 15:2863-9 - PubMed
- J Public Health Manag Pract. 2016 Sep-Oct;22(5):452-60 - PubMed
- Eval Program Plann. 2008 May;31(2):136-44 - PubMed
- Drug Alcohol Depend. 2003 Aug 20;71(2):195-206 - PubMed
- Prev Chronic Dis. 2019 Apr 25;16:E50 - PubMed
- Cancer. 2008 Feb 1;112(3):626-35 - PubMed
- J Subst Abuse Treat. 1997 Sep-Oct;14(5):445-55 - PubMed
- Cancer Epidemiol. 2016 Dec;45 Suppl 1:S13-S19 - PubMed
- Eval Program Plann. 2011 May;34(2):147-53 - PubMed
- Prev Chronic Dis. 2008 Apr;5(2):A47 - PubMed
- Eval Program Plann. 2017 Jun;62:73-80 - PubMed
- Cancer. 2013 Aug 1;119 Suppl 15:2855-62 - PubMed
- Cancer Epidemiol. 2016 Dec;45 Suppl 1:S50-S58 - PubMed
- Am J Prev Med. 2009 Sep;37(3):242-7 - PubMed
- J Subst Abuse Treat. 1998 May-Jun;15(3):201-11 - PubMed
- Cancer Causes Control. 2015 May;26(5):689-95 - PubMed
- Eval Program Plann. 2017 Jun;62:67-72 - PubMed
- JAMA. 2016 Jun 21;315(23):2564-2575 - PubMed
MeSH terms
Publication Types